TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05947500
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05947500
Drug: Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05197049
Drug: Guselkumab Dose 1
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
Study: NCT05197049
Drug: Guselkumab Dose 2
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 2) will be administered by SC injection.
Study: NCT05197049
Drug: Guselkumab Dose 3
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab (Dose 3) will be administered by SC injection.
Study: NCT06095089
Drug: JNJ-78278343
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-78278343 will be administered.
Study: NCT06095089
Drug: JNJ-87189401
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-87189401 will be administered.
Study: NCT06496178
Drug: Petosemtamab
Normalized name: Petosemtamab
DrugBank: Petosemtamab (DB18948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCLA-158
Study: NCT06303193
Drug: pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
Study: NCT06058377
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05297617
Drug: Anti-aromatase inhibitor
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily
Study: NCT05583708
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400mg IV
Study: NCT05583708
Drug: Lutetium Lu 177 dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.4GBq (200 mCi) IV
Study: NCT04947826
Drug: HLX10 (PD-1 antibody)
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
Study: NCT04947826
Drug: HLX04 (VEGF antibody)
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
Study: NCT05280743
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: exposure to opioids after Cesarean Section
Study: NCT04798781
Drug: Telatinib
Normalized name: Telatinib
DrugBank: Telatinib (DB15393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
Study: NCT04798781
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
Study: NCT06048081
Drug: zolbetuximab
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab
Study: NCT06377683
Drug: 177Lu-Dansyl-PSMA radioligand therapy
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
Study: NCT04922645
Drug: Ferric Citrate 1 gram Oral Tablet
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
Study: NCT05561751
Drug: GPC-100
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
Study: NCT05561751
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propranolol
Study: NCT05561751
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF
Study: NCT05493228
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
Study: NCT05249309
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
Study: NCT05124002
Drug: HAIC of FOLFOX
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
Study: NCT04660812
Drug: AB680
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AB680 is a cluster of differentiated CD73 Inhibitor
Study: NCT04660812
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
Study: NCT04660812
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab is a fully human anti-PD-1 monoclononal antibody
Study: NCT04660812
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is administered as part of standard chemotherapy regimen
Study: NCT04660812
Drug: m-FOLFOX-6 regimen
Normalized name: 6-amyl-m-cresol
DrugBank: Amylmetacresol (DB13908)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
Study: NCT04660812
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib is adminstered as part of standard chemotherapy regimen
Study: NCT05220098
Drug: TAK-280
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TAK-280 as IV infusion.
Study: NCT06127160
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1000 mg by mouth 3 times daily for 10 days
Study: NCT06127160
Drug: Cephalexin or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
Study: NCT06559306
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant will be administered orally.
Study: NCT06700720
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Study: NCT05533242
Drug: Lu-177 labeled 6A10-Fab-fragments
Normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
Study: NCT05218785
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 75 U in medial gastrocbemius head. x 3
Study: NCT04882878
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab dose 1 and dose 2 will be administered intravenously.
Study: NCT05142072
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal film
Study: NCT05236868
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
Study: NCT04844411
Drug: JNJ-67835989
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-67835989 will be administered orally.
Study: NCT06449651
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administrated intravenously.
Study: NCT04696809
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered subcutaneously.
Study: NCT04655807
Drug: JNJ-64304500
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64304500 will be administered as SC injection.
Study: NCT04655807
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab will be administered as SOC biological therapy.
Study: NCT04655807
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab will be administered as SOC biological therapy.
Study: NCT04886804
Drug: zongertinib
Normalized name: Zongertinib
DrugBank: Zongertinib (DB18762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zongertinib
Study: NCT06467825
Drug: Potassium Supplement
Normalized name: Potassium supplement
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be given a potassium supplement that will help prevent low blood potassium levels.
Study: NCT06467825
Drug: Furosemide 20 MG
Normalized name: furosemide 20 MG
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
Study: NCT06095102
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 will be administered orally.
Study: NCT05867550
Drug: Rifaximin 550 MG
Normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
Study: NCT05867550
Drug: Mebeverine 135 MG
Normalized name: mebeverine 135 MG
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
Study: NCT05541315
Drug: JNJ-88260237
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-88260237 will be administered orally.
Study: NCT06042478
Drug: Remibrutinib
Normalized name: Remibrutinib
DrugBank: Remibrutinib (DB16852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment
Study: NCT05867550
Drug: Psyllium Husk
Normalized name: Psyllium Husk
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
Study: NCT05867550
Drug: Amitriptyline Hydrochloride 25 MG
Normalized name: amitriptyline hydrochloride 25 MG
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
Study: NCT06042478
Drug: Placebo to remibrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by active treatment
Study: NCT06042478
Drug: Placebo to omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo followed by active comparator
Study: NCT06042478
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active comparator
Study: NCT04937543
Drug: Inahaled beclomethasone / formoterol / glycopyrronium
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
Study: NCT05635955
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated.
Study: NCT05660083
Drug: L-NMMA
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
Study: NCT05635955
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated.
Study: NCT05635955
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.3mg/kg esketamine will be co-administrated in both arms
Study: NCT00308841
Drug: Lidocaine (drug)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05985083
Drug: IMM47
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
Study: NCT00000236
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05964647
Drug: LSD (150 µg) + ketanserin (40 mg)
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose
Study: NCT05964647
Drug: LSD (150 µg) + olanzapine (10 mg)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose
Study: NCT05964647
Drug: LSD (150 µg) + lorazepam (2 mg)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose
Study: NCT05753007
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Custom-formulated full-spectrum solution high in cannabidiol
Study: NCT06050577
Drug: oral Semaglutide/Rybelsus
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
Study: NCT04675762
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
Study: NCT05083182
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab will be administered as subcutaneous injection.
Study: NCT05083182
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered as subcutaneous injection.
Study: NCT05498428
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered subcutaneously by manual injection.
Study: NCT05498428
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib will be administered as an oral tablet.
Study: NCT05498428
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administrated by IV infusion.
Study: NCT05498428
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered by IV infusion.
Study: NCT04628026
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
Study: NCT04898634
Drug: JNJ-78278343
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-78278343 will be administered.
Study: NCT05923073
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered subcutaneously.
Study: NCT05923073
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered intravenously.
Study: NCT06132958
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m\^2 of paclitaxel by IV infusion
Study: NCT05585671
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lupus patients without previous involvement of kidney are enrolled, and receive 2-year of 10mg/kg belimumab intravenously on the background of standard of care (SOC). During follow-up, we observe whether these patients will develop new-onset lupus nephritis.
Study: NCT06544616
Drug: JNJ-64042056
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64042056 will be administered intramuscularly.
Study: NCT05552157
Drug: Remternetug (SC)
Normalized name: Remternetug
DrugBank: Remternetug (DB18994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously every 12 weeks
Study: NCT05039710
Drug: JNJ-75220795
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-75220795 will be administered as SC injection.
Study: NCT04320342
Drug: Beclomethasone Dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study: NCT04320342
Drug: Glycopyrronium Bromide
Normalized name: Glycopyrronium bromide
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
Study: NCT04320342
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study: NCT05224089
Drug: Liposomal Bupivicaine/Bupivacaine Admixture
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL